Although it might seem like AI is the newest and hottest innovation in the industry, medical affairs professionals have been using some form of it for decades
From streamlining clinical trials to evaluating drug repurposing possibilities for new patient populations and addressing critical supply chain challenges, 2024 will be the year artificial
BenevolentAI has discovered a second novel target for idiopathic pulmonary fibrosis (IPF), which AstraZeneca has added to its drug development portfolio, resulting in a milestone payment to the Lon
Biogen has given an update on the rollout of its Eisai-partnered Alzheimer’s disease therapy Leqembi alongside its first-quarter results, showing that while the drug’s tak
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.